Michael J. LaBarre sold $1.3M of HALO
SVP, CHIEF TECHNICAL OFFICER at HALOZYME THERAPEUTICS, INC.. 21,697 shares at an average of $58.10, traded Feb 25, 2025, filed Feb 27, 2025.
Score components
- +15RoleOfficer
- +25Trade size$1.3M at market
- +5Share of holdings soldSold 11% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-005899, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 25, 2025 | SOpen-market sale Common Stock10b5-1 | -9,300 | $58.01 | $539k | 186,153 | Feb 27, 2025 |
| Feb 25, 2025 | SOpen-market sale Common Stock10b5-1 | -700 | $58.67 | $41k | 185,453 | Feb 27, 2025 |
| Feb 26, 2025 | SOpen-market sale Common Stock10b5-1 | -9,400 | $58.09 | $546k | 176,053 | Feb 27, 2025 |
| Feb 26, 2025 | SOpen-market sale Common Stock10b5-1 | -600 | $58.65 | $35k | 175,453 | Feb 27, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock10b5-1 | -1,597 | $58.25 | $93k | 173,856 | Feb 27, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock10b5-1 | -100 | $58.74 | $5,874 | 173,756 | Feb 27, 2025 |
Related signals
Other insiders at HALOZYME THERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.6M 60,000 shares | -8% | |
| 22Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $568k 5,230 shares | -9% | |
| 33Weak | HALOZYME THERAPEUTICS, INC. | Matthew L. Posard director | $2.0M 18,996 shares | -24% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $6.4M 60,000 shares | -8% | |
| 50Moderate | HALOsell HALOZYME THERAPEUTICS, INC. | Cortney Caudill SVP, CHIEF OPERATING OFFICER | $2.0M 28,857 shares | -84% | |
| 6Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $141k 2,000 shares | -5% | |
| 44Moderate | HALOZYME THERAPEUTICS, INC. | Cortney Caudill SVP, CHIEF OPERATING OFFICER | $278k 4,263 shares | -25% | |
| 10Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $59k 829 shares | -2% | |
| 23Weak | HALOZYME THERAPEUTICS, INC. | Helen Torley PRESIDENT AND CEO | $1.1M 16,569 shares | -2% | |
| 21Weak | HALOZYME THERAPEUTICS, INC. | Bernadette Connaughton director | $137k 2,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.